Clinical Trials Browser

Phase 1/2 × Cisplatin × 1 year × Clear all

NCT06694454 2026-05-27

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

Pathologic Complete Response, Carcinoma, Non-Small-Cell Lung

NCT06772623 2026-05-27

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05789082 2026-05-18

KRAScendo 170

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT05173142 2026-05-15

A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid Tumors

Phase 1/2 Completed

Gastrointestinal

Stomach Neoplasms

NCT07579195 2026-05-14

Consolidative Therapy After EV + Pembrolizumab in Muscle Invasive Bladder Cancer, REINFORCE Trial

Phase 1/2 Not yet recruiting

Urinary Bladder Neoplasms

NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Phase 1/2 Recruiting

Advanced NUT Carcinoma

NCT07397338 2026-05-12

Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors

Phase 1/2 Recruiting

GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms

NCT06802835 2026-05-11

EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma

Phase 1/2 Recruiting

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04083599 2026-05-06

GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors

Phase 1/2 Active not recruiting

DermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Colorectal Neoplasms

NCT07559929 2026-05-06

A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung CancerInhibitors or Platinum-Based Agents for Small Cell Lung Cancer.

Phase 1/2 Not yet recruiting

Small Cell Lung Carcinoma

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT06996782 2026-05-01

ALTAIR

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT01064648 2026-04-29

Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma

Phase 1/2 Active not recruiting

117 enrolled 23 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant, Solitary Fibrous Tumor, Pleural

NCT02535312 2026-04-17

Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin

Phase 1/2 Active not recruiting

30 enrolled 15 charts

Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT06741644 2026-04-15

A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumors

NCT06624059 2026-04-08

HORIZON 2

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04938583 2026-04-06

Oregovomab in Combination With Bevacizumab Plus Chemo in BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

Ovarian Neoplasms

NCT05516914 2026-04-01

A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Phase 1/2 Completed

Neoplasms

NCT03473743 2026-03-30

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Phase 1/2 Active not recruiting

125 enrolled 19 charts

Carcinoma, Transitional Cell

NCT03288545 2026-03-24

EV-103

Phase 1/2 Terminated

348 enrolled 1 FDA

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ureteral Neoplasms, Urethral Neoplasms, Urologic Neoplasms

NCT07392541 2026-03-23

Adebrelimab Combined With Gemcitabine, Cisplatin, and Simvastatin for Advanced Biliary Tract Cancer

Phase 1/2 Recruiting

Gastrointestinal

Advanced Biliary Tract Carcinoma

NCT03965234 2026-03-17

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases

Phase 1/2 Recruiting

GastrointestinalSarcoma

Bone Neoplasms, Sarcoma, Colorectal Neoplasms

NCT05410145 2026-03-12

A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation

Phase 1/2 Recruiting

KRAS P.G12C

NCT07466160 2026-03-12

A Phase Ib/II Study of 7MW3711 Combined With JS207 in Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Solid Tumor

NCT05229497 2026-03-09

A Phase Ib/II Study of AK112 in Combination With AK117 in Advanced Malignant Tumors

Phase 1/2 Active not recruiting

Advanced Malignant Tumors

NCT06162221 2026-03-09

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT07453394 2026-03-06

QLS5132 Combination Therapy in Advanced Solid Tumors

Phase 1/2 Not yet recruiting

GastrointestinalGynecologicThoracic

Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms

NCT03734692 2026-02-12

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer

Phase 1/2 Active not recruiting

24 enrolled 59 charts

Ovarian Cancer Recurrent

NCT06405230 2026-02-03

Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT03869190 2026-01-22

Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)

Phase 1/2 Completed

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT06428409 2026-01-22

MK-9999-02A

Phase 1/2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms, Colorectal Neoplasms

NCT04486833 2026-01-21

Acclaim-1

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06548412 2026-01-20

CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers

Phase 1/2 Recruiting

Gastrointestinal

Biliary Tract Neoplasms

NCT02989584 2026-01-07

A Phase II Study of Atezolizumab in Combination With Cisplatin + Gemcitabine Before Surgery to Remove the Bladder Cancer

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04203160 2025-12-31

Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)

Phase 1/2 Terminated

75 enrolled 17 charts

Gastrointestinal

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

Brain Neoplasms, Breast Neoplasms

NCT06512051 2025-12-23

A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Phase 1/2 Recruiting

Advanced Cancer

NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Phase 1/2 Active not recruiting

DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT03281369 2025-12-15

A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)

Phase 1/2 Completed

Gastrointestinal

Esophageal Neoplasms

NCT05664971 2025-12-02

JS004 Combined With Toripalimab and With Standard Chemotherapy Treat Patients With Advanced Lung Cancer

Phase 1/2 Completed

Advanced Lung Cancer

NCT06040970 2025-12-02

Sacituzumab Govitecan in Combination With Cisplatin in Platinum Sensitive Recurrent Ovarian and Endometrial Cancer

Phase 1/2 Recruiting

Ovarian Neoplasms, Uterine Neoplasms

NCT07258979 2025-12-02

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Phase 1/2 Recruiting

Nasopharyngeal Carcinoma, Recurrence

NCT07256782 2025-12-01

A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors

Phase 1/2 Recruiting

Other solid neoplasm

Advanced Solid Tumor

NCT02393794 2025-10-06

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

Phase 1/2 Active not recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05407675 2025-10-03

A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors

Phase 1/2 Completed

68 enrolled 27 charts

Neoplasms

NCT04956640 2025-09-25

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)

Phase 1/2 Recruiting

GastrointestinalGynecologicThoracic

Biliary Tract Neoplasms, Carcinoma, Non-Small-Cell Lung, Ovarian Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms

NCT06531434 2025-09-22

Establishing Best Treatment Strategy for T4 Esophageal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Esophageal Cancer TNM Staging Primary Tumor (T) T4

NCT03298893 2025-09-19

NiCOL

Phase 1/2 Completed

Uterine Cervical Neoplasms

NCT06543576 2025-08-15

External Beam Radiation Therapy and Brachytherapy With Chemotherapy and Immunotherapy for the Treatment of Stage IVB Cervical Cancer

Phase 1/2 Recruiting

Cervical Adenocarcinoma